Featured Research

from universities, journals, and other organizations

Nose Drop Drug Helps Fight AIDS-Related Cancer

Date:
February 15, 2000
Source:
University Of Southern California
Summary:
An anti-angiogenesis drug, delivered as a nose drop, can bring on the death of tumor cells and even result in remission in patients with AIDS- related Kaposi¹s Sarcoma (KS), according to a study published in the February issue of the Journal of Clinical Oncology by researchers from the USC/Norris Comprehensive Cancer Center.

An anti-angiogenesis drug, delivered as a nose drop, can bring on the death of tumor cells and even result in remission in patients with AIDS- related Kaposi¹s Sarcoma (KS), according to a study published in the February issue of the Journal of Clinical Oncology by researchers from the USC/Norris Comprehensive Cancer Center.

This is the first treatment aimed at disrupting the production of new blood vessels to be successful against the most common malignancy associated with the human immunodeficiency virus, for which there is currently no cure.

A total of 44 patients -- 42 men and 2 women -- with KS were enrolled in an open-label Phase I/II trial of IM862, a tiny protein normally made in the thymus gland. Five of the patients taking the drug experienced a complete remission, and 11 showed a partial remission, for a major response rate of 36 percent.

"And all this occurred with very few side effects, which were limited mostly to mild headaches," said the study¹s principal investigator, Parkash Gill, M.D., professor of medicine and pathology at the Keck School of Medicine of the University of Southern California.

IM862 not only works, but it works quickly: The median amount of time it took for patients in the Phase I/II trials to respond was six to eight weeks. "It can take as much as 20-some weeks to see a complete response," said Gill, "but that¹s still fairly rapid."

And the drug¹s response lasts, as well. For 21 of the patients, the stabilization or regression of their disease has lasted between 7 and 72 weeks or more (at the time the data was compiled) -- even after they stopped taking the drug. "We have a number of patients who after stopping therapy have still not relapsed," Gill said.

The trial was conducted at the USC/Norris Comprehensive Cancer Center and Massachusetts General Hospital. Gill first unveiled his findings at the 35th annual meeting of the American Society of Clinical Oncology last May.

IM862, a peptide, is in development at Cytran Inc., of Kirkland, Wash. Its anti-angiogenic effect appears to be the result of a reduction in the production of a hormone called vascular endothelial growth factor (VEGF), said Gill. VEGF is the hormone responsible for new blood-vessel growth in the body. IM862 also appears to have immune system effects, enhancing the production of chemicals like interleukin-12 and thereby stimulating the body¹s so-called natural killer (NK) cells.

These two actions are closely intertwined. "NK cells produce factors that are toxic to endothelial cells," Gill explained, which means they can slow the growth of blood vessels as well as attack the tumor itself.

Recent laboratory analyses have shown that animals with pancreatic tumors who are treated with IM862 not only have a reduced rate of tumor growth, but have lower levels of VEGF as well. "This confirms quite nicely that at least one of the ways the drug is working is by anti-angiogenesis," Gill said.

Phase III trials of IM862 are now underway at the USC/Norris. In addition, IM862 is currently being tested as a treatment for ovarian cancer, colorectal cancer and melanoma. Gill and his colleagues are planning to begin a trial for prostate cancer, as well.

###

EDITORS: See Anil Tulpule, David T. Scadden, Byron M. Espina, Suzanne Cabriales, Walter Howard, Kathleen Shea, Parkash Gill, "Results of a Randomized Study of IM862 Nasal Solution in the Treatment of AIDS-related Kaposi¹s Sarcoma," Journal of Clinical Oncology, Vol. 18, No. 4, [February] 2000.


Story Source:

The above story is based on materials provided by University Of Southern California. Note: Materials may be edited for content and length.


Cite This Page:

University Of Southern California. "Nose Drop Drug Helps Fight AIDS-Related Cancer." ScienceDaily. ScienceDaily, 15 February 2000. <www.sciencedaily.com/releases/2000/02/000215064508.htm>.
University Of Southern California. (2000, February 15). Nose Drop Drug Helps Fight AIDS-Related Cancer. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2000/02/000215064508.htm
University Of Southern California. "Nose Drop Drug Helps Fight AIDS-Related Cancer." ScienceDaily. www.sciencedaily.com/releases/2000/02/000215064508.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) — Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) — At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) — Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins